InsidersTradesSigma
Track the Lucira Health, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Lucira Health, Inc. has published 32 insider filings. The latest transaction was disclosed on 13 March 2023 (Cession). Among the most active insiders: Kashmolah Ghazi. The full history is accessible without an account.
32
Insider Decl.
n/a
Thresholds
€132,813
3 ops.
Buy Volume
€289,693
22 ops.
Sell Volume
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 March 2023
Declarations32 total
30,102 shares@ US$1.1527.1% of flowCommon StockSEC:0001209191-23-018223:0
10,674 shares@ US$1.1495.5% of flowCommon StockSEC:0001209191-23-018225:0
8,405 shares@ US$1.0023.7% of flowCommon StockSEC:0001209191-23-018219:0
574,666 shares@ US$0.8277.0% of flowCommon StockSEC:0001209191-23-018261:0
5,028 shares@ US$0.271.1% of flowCommon StockSEC:0001209191-23-011047:0
4,263 shares@ US$0.161.9% of flowCommon StockSEC:0001209191-22-062409:0
3,461,764 sharesCommon StockSEC:0001667731-22-000447:0
3,429 shares@ US$0.333.3% of flowCommon StockSEC:0001209191-22-060495:0
7,537 shares@ US$0.422.7% of flowCommon StockSEC:0001209191-22-060487:0
8,011 shares@ US$0.382.6% of flowCommon StockSEC:0001209191-22-060480:0
1,583 shares@ US$0.364.5% of flowCommon StockSEC:0001209191-22-059999:0
9,666 shares@ US$0.423.2% of flowCommon StockSEC:0001209191-22-058925:0
4,790 shares@ US$0.351.4% of flowCommon StockSEC:0001209191-22-058008:0
17,052 shares@ US$1.3971.1% of flowCommon StockSEC:0001209191-22-051033:0
343 shares@ US$1.3820.6% of flowCommon StockSEC:0001209191-22-050767:0
20,000 shares@ US$1.826.3% of flowCommon StockSEC:0001209191-22-050460:0
Canonical exit: 14 Dec 2022 (T+90)
191 shares@ US$1.6948.0% of flowCommon StockSEC:0001209191-22-048920:0
8,580 shares@ US$1.7212.3% of flowCommon StockSEC:0001209191-22-047931:0
1,500 shares@ US$1.932.6% of flowCommon StockSEC:0001209191-22-047928:0
19,074 shares@ US$2.5242.2% of flowCommon StockSEC:0001209191-22-047309:0
19,074 shares@ US$2.8347.3% of flowCommon StockSEC:0001209191-22-046962:0
37,109 shares@ US$2.0057.4% of flowCommon StockSEC:0001209191-22-041962:0
1,289 shares@ US$4.689.1% of flowCommon StockSEC:0001209191-22-041963:0
1,321 shares@ US$1.4579.4% of flowCommon StockSEC:0001209191-22-041961:0
890 shares@ US$4.6892.0% of flowCommon StockSEC:0001209191-22-041964:0
25 of 32 declarations
关于 Lucira Health, Inc.
Lucira Health, Inc. 是一家总部位于美国、在纳斯达克上市（股票代码LHDX）的医疗技术公司。该公司于2013年以DiAssess Inc.之名成立，后更名为Lucira Health，总部设在加利福尼亚州埃默里维尔。其商业模式专注于开发、制造和商业化用于家庭使用的传染病诊断测试，其价值主张围绕速度、易用性和传统实验室之外的分散式测试。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai)) Lucira的旗舰产品是其家用COVID-19测试，该产品成为美国最早获授权的快速分子自检产品之一。该产品在疫情推动的分散式诊断需求激增期间为公司带来了显著的知名度。随着时间的推移，Lucira还将其自身定位为一家更广泛的呼吸道测试平台公司，其提交给美国证券交易委员会（SEC）的文件和投资者沟通中提及流感及其他传染病测试是其产品和开发战略的一部分。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai)) 从竞争角度来看，Lucira在一个拥挤的体外诊断市场中运营，该市场由规模更大、商业基础设施更深厚、监管范围更广、资产负债表更强的参与者主导。其差异化在于结合了分子检测、家用和快速周转时间。然而，这一利基市场严重依赖于疫情后消费者需求的轨迹，以及Lucira能否超越单一的COVID驱动收入来源进行扩张。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai)) 从地理上看，Lucira的运营足迹主要以美国为中心，根植于加利福尼亚州，并通过美国的纳斯达克市场进行交易。该公司还在其提交给SEC的材料中提及国际扩张计划，并强调了制造和商业化合作伙伴关系作为其规模化努力的一部分。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai)) 最近最重要的进展是该公司财务状况恶化，并于2023年2月申请破产保护（Chapter 11）。在重组过程之后，Lucira的资产被出售给辉瑞，这从根本上改变了原始独立发行人的投资案例。对于投资者而言，Lucira最好被理解为一个疫情时代的诊断增长故事，但随着COVID检测需求正常化和公司战略选择收窄，该故事后来面临急剧的重置。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312523044968/d642141dex991.htm?utm_source=openai))
